In the most recent trials, it has been observed that the addition of rituximab to CHOP (R-CHOP) improved patient outcomes even more; now, R-CHOP is the latest standard of care.5, 6Individuals age >60 years comprise a significant number of the patients who are diagnosed with diffuse large cell lymphoma in the U.S. each year.6, 7 Randomized trials have shown that patients in this age group respond t